[{'address1': '15 Maurice Paykel Place', 'address2': 'East Tamaki', 'city': 'Auckland', 'zip': '2013', 'country': 'New Zealand', 'phone': '64 9 574 0100', 'fax': '64 9 574 0158', 'website': 'https://www.fphcare.com', 'industry': 'Medical Instruments & Supplies', 'industryKey': 'medical-instruments-supplies', 'industryDisp': 'Medical Instruments & Supplies', 'sector': 'Healthcare', 'sectorKey': 'healthcare', 'sectorDisp': 'Healthcare', 'longBusinessSummary': 'Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, it provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.', 'fullTimeEmployees': 6978, 'companyOfficers': [{'maxAge': 1, 'name': 'Mr. Lewis G. Gradon', 'age': 62, 'title': 'MD, CEO & Executive Director', 'yearBorn': 1961, 'fiscalYear': 2024, 'totalPay': 2641867, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lyndal  York', 'title': 'Chief Financial Officer', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andy  Niccol', 'title': 'COO & GM of Respiratory Humidification', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Andrew  Somervell', 'title': 'Vice President of Products & Technology', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Hayden  Brown', 'title': 'Head of Capital Markets & Investor Relations', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Raelene  Leonard', 'title': 'Company Secretary & General Counsel', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Daniel  Adolph', 'title': 'Senior Communications & Investor Relations Manager', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Justin  Callahan', 'title': 'VP of Sales & Marketing and President of North America & Europe', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Nicola  Talbot', 'title': 'Vice President of Human Resources', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jonathan  Rhodes', 'title': 'Vice President of Supply Chain, Facilities & Sustainability', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}], 'auditRisk': 6, 'boardRisk': 5, 'compensationRisk': 8, 'shareHolderRightsRisk': 5, 'overallRisk': 5, 'governanceEpochDate': 1725148800, 'compensationAsOfEpochDate': 1735603200, 'maxAge': 86400, 'priceHint': 2, 'previousClose': 34.76, 'open': 34.68, 'dayLow': 34.6, 'dayHigh': 35.43, 'regularMarketPreviousClose': 34.76, 'regularMarketOpen': 34.68, 'regularMarketDayLow': 34.6, 'regularMarketDayHigh': 35.43, 'dividendRate': 0.38, 'dividendYield': 0.011, 'exDividendDate': 1719360000, 'payoutRatio': 1.5996001, 'fiveYearAvgDividendYield': 1.34, 'beta': 0.419, 'trailingPE': 168.52382, 'forwardPE': 57.080643, 'volume': 166664, 'regularMarketVolume': 166664, 'averageVolume': 370542, 'averageVolume10days': 476144, 'averageDailyVolume10Day': 476144, 'bid': 35.39, 'ask': 35.42, 'marketCap': 20667052032, 'fiftyTwoWeekLow': 18.58, 'fiftyTwoWeekHigh': 35.43, 'priceToSalesTrailing12Months': 11.858534, 'fiftyDayAverage': 30.2968, 'twoHundredDayAverage': 25.70145, 'trailingAnnualDividendRate': 0.415, 'trailingAnnualDividendYield': 0.011939011, 'currency': 'AUD', 'enterpriseValue': 20391106560, 'profitMargins': 0.076079994, 'floatShares': 581245345, 'sharesOutstanding': 583980032, 'heldPercentInsiders': 0.10170999, 'heldPercentInstitutions': 0.39228, 'impliedSharesOutstanding': 586284032, 'bookValue': 3.015, 'priceToBook': 11.737976, 'lastFiscalYearEnd': 1711843200, 'nextFiscalYearEnd': 1743379200, 'mostRecentQuarter': 1711843200, 'earningsQuarterlyGrowth': -0.836, 'netIncomeToCommon': 132600000, 'trailingEps': 0.21, 'forwardEps': 0.62, 'pegRatio': 2.99, 'lastSplitFactor': '5:1', 'lastSplitDate': 1096243200, 'enterpriseToRevenue': 11.7, 'enterpriseToEbitda': 45.843, '52WeekChange': 0.75910926, 'SandP52WeekChange': 0.23285389, 'lastDividendValue': 0.213742, 'lastDividendDate': 1719360000, 'exchange': 'ASX', 'quoteType': 'EQUITY', 'symbol': 'FPH.AX', 'underlyingSymbol': 'FPH.AX', 'shortName': 'F&P HEALTH FPO NZX [FPH]', 'longName': 'Fisher & Paykel Healthcare Corporation Limited', 'firstTradeDateEpochUtc': 1006297200, 'timeZoneFullName': 'Australia/Sydney', 'timeZoneShortName': 'AEST', 'uuid': 'eaaafdbf-d4f4-3362-8e34-a2d3135c79e4', 'messageBoardId': 'finmb_875015', 'gmtOffSetMilliseconds': 36000000, 'currentPrice': 35.39, 'targetHighPrice': 29.92, 'targetLowPrice': 20.08, 'targetMeanPrice': 25.03, 'targetMedianPrice': 25.24, 'recommendationMean': 3.0, 'recommendationKey': 'hold', 'numberOfAnalystOpinions': 8, 'totalCash': 82000000, 'totalCashPerShare': 0.141, 'ebitda': 444800000, 'totalDebt': 189100000, 'quickRatio': 0.904, 'currentRatio': 1.831, 'totalRevenue': 1742800000, 'debtToEquity': 10.75, 'revenuePerShare': 2.995, 'returnOnAssets': 0.09847, 'returnOnEquity': 0.075500004, 'freeCashflow': 45700000, 'operatingCashflow': 429600000, 'earningsGrowth': -0.84, 'revenueGrowth': 0.055, 'grossMargins': 0.59927, 'ebitdaMargins': 0.25522, 'operatingMargins': 0.21382, 'financialCurrency': 'NZD', 'trailingPegRatio': None}]